Reviva Pharmaceuticals Holdings
October 10, 2023 - by Joey Ramson
$RVPH bottomed out in August of last year, at which time the company came out with positive trial results for their phase 2 study of RP5063 (brilaroxazine) for Acute Schizophrenia. Since then the stock has gained in value and has done a pretty good job of holding those gains.
